Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | TACR2 | P21452 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147259 | 0.89 | SLC6A2 (0.52) | SLC6A2PDE4DPDPK1MTORTACR2 | |
| SCHEMBL12162838 | 0.89 | SLC6A2 (0.52) | SLC6A2PDE4DPDPK1MTORTACR2 | |
| SCHEMBL8714420 | 0.84 | SLC6A2 (0.48) | SLC6A2PDE4DPDPK1MTORTACR2 | |
| SCHEMBL8718030 | 0.84 | SLC6A2 (0.48) | SLC6A2PDE4DPDPK1MTORTACR2 | |
| SCHEMBL8714419 | 0.84 | SLC6A2 (0.48) | SLC6A2PDE4DPDPK1MTORTACR2 | |
| SCHEMBL23225625 | 0.83 | SLC6A2 (0.52) | SLC6A2PDE4DPDPK1MTORTACR2 | |
| SCHEMBL26354181 | 0.82 | SLC6A2 (0.51) | SLC6A2PDE4DPDPK1MTORTACR2 | |
| SCHEMBL2692987 | 0.80 | TACR1 (0.38) | SLC6A2PDPK1MTORCYP2C19ALDH1A1 | |
| SCHEMBL2692800 | 0.80 | BCHE (0.37) | SLC6A2PDPK1MTORCYP2C19ALDH1A1 | |
| SCHEMBL2694556 | 0.80 | BCHE (0.37) | SLC6A2PDPK1MTORCYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088904-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090092981-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090092981-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | HNRNPM, POLM, RNMT | SLC6A2 4175/4885PDE4D 3903/4885PDPK1 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.